Clinical updates, including trial initiations, enrollment status and data readouts and publications: 89bio, AB Science, Actinium, Alexion, Alzprotect, Astrazeneca, Biontech, Blade, Boehringer, Caelum, Cassava, Celltrion, Cyxone, Daiichi, Diamedica, Diamyd, Enanta, Frequency, Humanigen, Immunity, Incyte, Inflarx, LB, Lilly, Myovant, Novartis, Pfizer, Pharmabcine, Regeneron.

Results from the first trial testing the oral autotaxin inhibitor ziritaxestat in adults with diffuse cutaneous systemic sclerosis have encouraged its originator, Galapagos NV, to explore next steps for the program, it said on Sept. 11.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Anavex, Aura, Atara, Bicycle, Biogen, Cancer Prevention, Celltrion, Clene, Galapagos, Genentech, GW, Immunic, Lilly, Lyra, Neurocrine, Novartis, Partner, Prothena, Reveragen, Santhera, Voyager.

A pivotal test of Satsuma Pharmaceuticals Inc.'s dry powder acute migraine candidate, STS-101, found neither of two doses evaluated met the co-primary endpoints, freeing people from pain or their most bothersome symptom two hours post-administration.

HONG KONG – Sanofi SA has finally ended its clinical development of Hanmi Pharmaceutical Co. Ltd.’s efpeglenatide as a type 2 diabetes treatment, and the Korean firm is now considering how to move forward with developing the once-weekly GLP-1 receptor agonist, which employs Hanmi's Lapscovery delivery technology.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Anavex, Arbor, Astrazeneca, Avillion, Bayer, Biohaven, Boehringer Ingelheim, Corcept, Corvus, Diffusion, Forte, Gemini, Haliodx, Histogen, Imcheck, Ocular, Recce, Roche, Sanofi, Satsuma, Seneca, Sobi, Sutro, Takeda, Theratechnologies, VBL, Vertex, Zogenix.

Shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) climbed 72.8% to $31.86 on Sept. 9 following news that its FDA-approved schizophrenia drug, Caplyta (lumateperone), could also help improve bipolar depression.